CN113248594B - 一种重组凝血因子viii及其应用 - Google Patents

一种重组凝血因子viii及其应用 Download PDF

Info

Publication number
CN113248594B
CN113248594B CN202110762308.XA CN202110762308A CN113248594B CN 113248594 B CN113248594 B CN 113248594B CN 202110762308 A CN202110762308 A CN 202110762308A CN 113248594 B CN113248594 B CN 113248594B
Authority
CN
China
Prior art keywords
recombinant
factor viii
ser
bdd
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110762308.XA
Other languages
English (en)
Other versions
CN113248594A (zh
Inventor
张隆基
宫洁
章睿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Meikang Geno Immune Biotechnology Co ltd
Original Assignee
Beijing Meikang Geno Immune Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Meikang Geno Immune Biotechnology Co ltd filed Critical Beijing Meikang Geno Immune Biotechnology Co ltd
Publication of CN113248594A publication Critical patent/CN113248594A/zh
Priority to EP22794558.1A priority Critical patent/EP4330276A1/en
Priority to JP2023560862A priority patent/JP2024514790A/ja
Priority to PCT/CN2022/085853 priority patent/WO2022228087A1/en
Application granted granted Critical
Publication of CN113248594B publication Critical patent/CN113248594B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/44Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Abstract

本发明涉及一种重组凝血因子VIII及其应用。所述重组凝血因子VIII的B结构域包括80%以上的SEQ ID NO:1或SEQ ID NO:2所示的氨基酸序列。所述重组凝血因子VIII的B结构域经过基因改造,富含糖基化位点,具备高效的凝血功能且易于分泌到胞外,易于与辅助因子如凝血酶(FIIa)等相互作用,此外,抗体反应低,能够有效保障治疗效果,降低免疫排斥风险,节约治疗成本。

Description

一种重组凝血因子VIII及其应用
技术领域
本发明属于生物技术领域,涉及一种重组凝血因子VIII及其应用。
背景技术
A型血友病(HemophiliaA,HA)又名遗传性抗血友病球蛋白缺乏症或FⅧ缺乏症,是一种是由凝血因子VIII的基因(FⅧ基因或F8基因)的遗传缺陷引起的凝血障碍。目前对HA的治疗主要为基于血浆源性凝血因子或外源培养的重组蛋白的蛋白置换疗法(proteinreplacement therapy,RPT),但PRT存在半衰期短、成本高及治疗周期长等局限性。
基因治疗(gene therapy)是指将外源正常基因导入靶细胞,以纠正或补偿缺陷和异常基因引起的疾病,以达到治疗目的。目前,基因治疗被认为是最有前景的HA治疗方法。
有研究对人类F8基因的分析显示其表达蛋白具有明显的结构域,表示为A1-A2-B-A3-C1-C2,B结构域由非常大的外显子编码,含有由连接寡糖的天门冬酰胺(N)组成的高度保守区。Miao等人指出,B结构域的部分缺失,保留N端226-氨基酸延伸,其中包含六个完整的天门冬酰胺连接的糖基化位点,能够使F8的体外分泌增加10倍(参见Miao,H.Z.,Sirachainan,N.,Palmer,L.,Kucab,P.,Cunningham,M.A.et al.Bioengineering ofcoagulation factor VIII for improved secretion.Blood,2004,103(9),3412-3419.)。但目前利用B结构域缺失的F8基因(F8-BDD)进行基因治疗的方法存在蛋白分泌和功能较低、F8病毒载体转染效率低以及产生抗体和抑制物反应(免疫排斥)等问题。
综上所述,提供一种重组凝血因子VIII,具备高效的凝血功能,且体内抗体反应低,对于HA基因治疗领域具有重要意义。
发明内容
针对现有技术的不足和实际需求,本发明提供一种重组凝血因子VIII及其应用,所述重组凝血因子VIII富含糖基化位点,具备高效的凝血功能且易于分泌到胞外,能够高效纠正A型血友病,且抗体反应低。
为达上述目的,本发明采用以下技术方案:
第一方面,本发明提供一种重组凝血因子VIII,所述重组凝血因子VIII的B结构域包括80%以上的SEQ ID NO.1或SEQ ID NO.2所示的氨基酸序列。
本发明的重组凝血因子VIII中富含糖基化位点序列,具备高效的凝血功能且易于分泌到胞外,易于与辅助因子如凝血酶(FIIa)等相互作用,此外,抗体反应低,能够有效保障治疗效果,降低免疫排斥风险,节约治疗成本。
SEQ ID NO.1:
EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNATTIQNVSSNNSLSNNLISTDNTSSEENNDSKNVSSNNSAPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVT。
SEQ ID NO.2:
EDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVT。
第二方面,本发明提供一种重组凝血因子VIII的编码基因,所述重组凝血因子VIII的编码基因包括SEQ ID NO:3或SEQ ID NO:4所示的核酸序列。
SEQ ID NO:3:
ctccaataattcagcgcccccagtattgaaacgccaccagagggagatcaccagaaccacactgcagtcagaccaagaggaaattgactatgatgacacaatcagtgtcgaaatgaaaaaagaagactttgatatttacgatgaggatgaaaatcagtcaccaagatcctttcaaaaaaaaacccgacattattttatagcagccgtcgaacggttgtgggattatggcatgagctcaagtccacatgtactgagaaatagggcgcagtcaggaagcgtaccccagtttaagaaggttgtattccaagaattcacagacggtagctttacccagccgctttatcgaggagagttgaatgagcaccttggtttgctgggaccgtacatccgcgcagaagtcgaagacaatataatggtcacctttcggaaccaagcctccaggccatacagtttctacagttctctgatctcatacgaggaagatcagaggcaaggagcagaaccaaggaagaacttcgtgaaaccaaacgagacaaagacctatttctggaaagttcagcatcatatg。
SEQ ID NO:4:
atgtcagacaagaggaatgtcatcctgttttctgtatttgatgagaaccgaagctggtacctcacagagaatatacaacgctttctccccaatccagctggagtgcagcttgaggatccggagtttcaggcatccaatatcatgcattctataaacgggtatgtatttgattctttgcagttgagtgtgtgtctgcatgaggttgcctactggtacattctgtctataggggcgcagacggatttcctttcagtgttcttcagcgggtatacatttaaacataagatggtatatgaggacaccttgacattgtttccattttccggcgaaaccgtattcatgtcaatggagaacccagggttgtggatactcggttgccataatagtgacttcagaaaccgagggatgacggcccttctcaaagtaagttcatgtgataagaataccggtgattactacgaagatagctatgaggatattagcgcctacttgcttagcaagaataacgctattgaacctaggagcttttcccagaatagccgacatcctagcactcgccaaaaacagtttaatgcgacaactatccctgagaacgatattgagaaaactgatccctggtttgcacatcgcactcctatgccaaagatccaaaacgtgagcagctctgacctccttatgttgcttagacaatctcccacacctcatggactctcactttccgatctgcaggaggcgaagtatgaaaccttctcagacgacccatccccaggagccatagactcaaacaatagtctctcagaaatgacgcactttagacctcaactccatcacagtggggatatggtatttacccccgagagtggtctgcagcttaggcttaatgaaaaattgggaaccaccgctgcaacggaactcaaaaaactggacttcaaggtttctagcacgtcaaacaatcttatatcaaccataccatccgacaaccttgccgcaggaaccgataacacatcaagcctggggcctccatcaatgccggtgcactatgattcacagttggatactaccctcttcgggaagaaaagttcaccgctgactgaaagcggtggcccactgtctctgagtgaagagaataatgattctaaacttctcgagagcggcctcatgaatagtcaggagagttcttgggggaaaaatgttagcagtactgagagcggacggctcttcaaaggtaagcgggcacatgggcccgctcttctgactaaggataacgctttgttcaaagttagcatatcactcctgaaaactaacaagacctcaaataattctgcaacgaaccggaagacccatattgacggtccaagtttgctcatcgagaactccccgagtgtatggcagaacattcttgagagcgataccgagtttcccccggtactcaagaggcatcagcgggagattacgcgaaccacactccagtccgatcaggaagaaattgattatgacgatactatcagtgtagagatgaaaaaagaagactttgacatctatgatgaggacgagaaccagtctccacgaagctttcagaaaaaaacaaggcactattttatcgccgctgttgaacggctgtgggactacggtatgtcctcttcaccccacgtgctgcggaaccgggcccagtcaggctcagtaccccaattcaagaaggtggtattccaggaatttaccgatggatctttcacgcaacctctttaccgaggtgagctgaacgaacatcttggccttctcggtccttatattagagcagaggtggaagacaatataatggtcacctttcggaaccaagcctccaggccatacagtttctacagttctctgatctcatacgaggaagatcagaggcaaggagcagaaccaaggaagaacttcgtgaaaccaaacgagacaaagacctatttctggaaagttcagcatcatatg。
优选地,所述重组凝血因子VIII的编码基因包括SEQ ID NO:5或SEQ ID NO:6所示的核酸序列。
SEQ ID NO:5:
atgcagatcgaactgagcacctgcttcttcctgtgtctcctgagattctgctttagtgctaccagacggtattacctgggagccgtcgagctgagttgggattacatgcagtccgacctcggagaactgcctgtggatgcacgctttccaccaagagtgcctaagtcattcccattcaacacctcagtcgtgtataagaagactctgttcgtcgagtttactgatcacctgttcaatatcgctaaacctagaccaccctggatgggactgctgggtcctacaatccaggcagaggtctatgacactgtggtgattacacttaagaacatggcttcccatcctgtcagtcttcatgctgttggtgtatcctactggaaagcttctgagggagctgaatatgatgatcagaccagtcaaagggagaaagaagatgataaagtcttccctggtggaagccatacatatgtctggcaggtcctgaaagagaatggtccaatggcctctgacccactgtgccttacctactcatatctttctcatgtggacctggtaaaagacttgaattcaggcctcattggagccctactagtatgtagagaagggagtctggccaaggaaaagacacagaccttgcacaaatttatactactttttgctgtatttgatgaagggaaaagttggcactcagaaacaaagaactccttgatgcaggatagggatgctgcatctgctcgggcctggcctaaaatgcacacagtcaatggttatgtaaacaggtctctgccaggtctgattggatgccacaggaaatcagtctattggcatgtgattggaatgggcaccactcctgaagtgcactcaatattcctcgaaggtcacacatttcttgtgaggaaccatcgccaggcgtccttggaaatctcgccaataactttccttactgctcaaacactcttgatggaccttggacagtttctactgttttgtcatatctcttcccaccaacatgatggcatggaagcttatgtcaaagtagacagctgtccagaggaaccccaactacgaatgaaaaataatgaagaagcggaagactatgatgatgatcttactgattctgaaatggatgtggtcaggtttgatgatgacaactctccttcctttatccaaattcgctcagttgccaagaagcatcctaaaacttgggtacattacattgctgctgaagaggaggactgggactatgctcccttagtcctcgcccccgatgacagaagttataaaagtcaatatttgaacaatggccctcagcggattggtaggaagtacaaaaaagtccgatttatggcatacacagatgaaacctttaagactcgtgaagctattcagcatgaatcaggaatcttgggacctttactttatggggaagttggagacacactgttgattatatttaagaatcaagcaagcagaccatataacatctaccctcacggaatcactgatgtccgtcctttgtattcaaggagattaccaaaaggtgtaaaacatttgaaggattttccaattctgccaggagaaatattcaaatataaatggacagtgactgtagaagatgggccaactaaatcagatcctcggtgcctgacccgctattactctagtttcgttaatatggagagagatctagcttcaggactcattggccctctcctcatctgctacaaagaatctgtagatcaaagaggaaaccagataatgtcagacaagaggaatgtcatcctgttttctgtatttgatgagaaccgaagctggtacctcacagagaatatacaacgctttctccccaatccagctggagtgcagcttgaggatccagaatttcaggccagtaatataatgcactccatcaacggatatgtctttgactccttgcaactctcagtgtgtcttcacgaggtggcctattggtatattctcagcataggggcccagactgactttctgtctgtcttcttcagcggatatacttttaagcataagatggtttatgaggatacattgacattgttccctttcagtggggagaccgtctttatgtctatggaaaatcctgggctctggatactcggttgccacaatagtgacttccgaaatcgcggaatgacagctctgctgaaagtgtccagttgtgacaaaaacaccggggactattacgaagacagctatgaagatataagtgcatatttgctcagcaagaacaatgcgattgagccaaggtctttcagtcaaaatgctactaccatacagaatgtctcttccaataacagcctctcaaacaacctcatctcaactgacaacacttcttctgaggagaacaatgacagtaagaatgtgtcctccaataattcagcgcccccagtattgaaacgccaccagagggagatcaccagaaccacactgcagtcagaccaagaggaaattgactatgatgacacaatcagtgtcgaaatgaaaaaagaagactttgatatttacgatgaggatgaaaatcagtcaccaagatcctttcaaaaaaaaacccgacattattttatagcagccgtcgaacggttgtgggattatggcatgagctcaagtccacatgtactgagaaatagggcgcagtcaggaagcgtaccccagtttaagaaggttgtattccaagaattcacagacggtagctttacccagccgctttatcgaggagagttgaatgagcaccttggtttgctgggaccgtacatccgcgcagaagtcgaagacaatataatggtcacctttcggaaccaagcctccaggccatacagtttctacagttctctgatctcatacgaggaagatcagaggcaaggagcagaaccaaggaagaacttcgtgaaaccaaacgagacaaagacctatttctggaaagttcagcatcatatggcacccactaaagatgagtttgactgcaaagcctgggcttatttctctgatgttgacctggaaaaagatgtgcactcaggcctgattggaccccttctggtctgccacactaacacactgaaccctgctcatgggagacaagtgacagtacaggaatttgctctgtttttcaccatctttgatgagaccaaaagctggtacttcactgaaaatatggaaagaaactgcagggctccctgcaatatccagatggaagatcccacttttaaagagaattatcgcttccatgcaatcaatggctacataatggatacactacctggcttagtaatggctcaggatcaaaggattcgatggtatctgctcagcatgggcagcaatgaaaacatccattctattcatttcagtggacatgtgttcactgtacgaaaaaaagaggagtataaaatggcactgtacaatctctatccaggtgtttttgagacagtggaaatgttaccatccaaagctggaatttggcgggtggaatgccttattggcgagcatctacatgctgggatgagcacactttttctggtgtacagcaataagtgtcagactcccctgggaatggcttctggacacattagagattttcagattacagcttcaggacaatatggacagtgggccccaaagctggccagacttcattattccggatcaatcaatgcctggagcaccaaggagcccttttcttggatcaaggtggatctgttggcaccaatgattattcacggcatcaagacccagggtgcccgtcagaagttctccagcctctacatctctcagtttatcatcatgtatagtcttgatgggaagaagtggcagacttatcgaggaaattccactggaaccttaatggtcttctttggcaatgtggattcatctgggataaaacacaatatttttaaccctccaattattgctcgatacatccgtttgcacccaactcattatagcattcgcagcactcttcgcatggagttgatgggctgtgatttaaatagttgcagcatgccattgggaatggagagtaaagcaatatcagatgcacagattactgcttcatcctactttaccaatatgtttgccacctggtctccttcaaaagctcgacttcacctccaagggaggagtaatgcctggagacctcaggtgaataatccaaaagagtggctgcaagtggacttccagaagacaatgaaagtcacaggagtaactactcagggagtaaaatctctgcttaccagcatgtatgtgaaggagttcctcatctccagcagtcaagatggccatcagtggactctcttttttcagaatggcaaagtaaaggtttttcagggaaatcaagactccttcacacctgtggtgaactctctagacccaccgttactgactcgctaccttcgaattcacccccagagttgggtgcaccagattgccctgaggatggaggttctgggctgcgaggcacaggacctctactga。
SEQ ID NO:6:
atgcagatcgaactgagcacctgcttcttcctgtgtctcctgagattctgctttagtgctaccagacggtattacctgggagccgtcgagctgagttgggattacatgcagtccgacctcggagaactgcctgtggatgcacgctttccaccaagagtgcctaagtcattcccattcaacacctcagtcgtgtataagaagactctgttcgtcgagtttactgatcacctgttcaatatcgctaaacctagaccaccctggatgggactgctgggtcctacaatccaggcagaggtctatgacactgtggtgattacacttaagaacatggcttcccatcctgtcagtcttcatgctgttggtgtatcctactggaaagcttctgagggagctgaatatgatgatcagaccagtcaaagggagaaagaagatgataaagtcttccctggtggaagccatacatatgtctggcaggtcctgaaagagaatggtccaatggcctctgacccactgtgccttacctactcatatctttctcatgtggacctggtaaaagacttgaattcaggcctcattggagccctactagtatgtagagaagggagtctggccaaggaaaagacacagaccttgcacaaatttatactactttttgctgtatttgatgaagggaaaagttggcactcagaaacaaagaactccttgatgcaggatagggatgctgcatctgctcgggcctggcctaaaatgcacacagtcaatggttatgtaaacaggtctctgccaggtctgattggatgccacaggaaatcagtctattggcatgtgattggaatgggcaccactcctgaagtgcactcaatattcctcgaaggtcacacatttcttgtgaggaaccatcgccaggcgtccttggaaatctcgccaataactttccttactgctcaaacactcttgatggaccttggacagtttctactgttttgtcatatctcttcccaccaacatgatggcatggaagcttatgtcaaagtagacagctgtccagaggaaccccaactacgaatgaaaaataatgaagaagcggaagactatgatgatgatcttactgattctgaaatggatgtggtcaggtttgatgatgacaactctccttcctttatccaaattcgctcagttgccaagaagcatcctaaaacttgggtacattacattgctgctgaagaggaggactgggactatgctcccttagtcctcgcccccgatgacagaagttataaaagtcaatatttgaacaatggccctcagcggattggtaggaagtacaaaaaagtccgatttatggcatacacagatgaaacctttaagactcgtgaagctattcagcatgaatcaggaatcttgggacctttactttatggggaagttggagacacactgttgattatatttaagaatcaagcaagcagaccatataacatctaccctcacggaatcactgatgtccgtcctttgtattcaaggagattaccaaaaggtgtaaaacatttgaaggattttccaattctgccaggagaaatattcaaatataaatggacagtgactgtagaagatgggccaactaaatcagatcctcggtgcctgacccgctattactctagtttcgttaatatggagagagatctagcttcaggactcattggccctctcctcatctgctacaaagaatctgtagatcaaagaggaaaccagataatgtcagacaagaggaatgtcatcctgttttctgtatttgatgagaaccgaagctggtacctcacagagaatatacaacgctttctccccaatccagctggagtgcagcttgaggatccggagtttcaggcatccaatatcatgcattctataaacgggtatgtatttgattctttgcagttgagtgtgtgtctgcatgaggttgcctactggtacattctgtctataggggcgcagacggatttcctttcagtgttcttcagcgggtatacatttaaacataagatggtatatgaggacaccttgacattgtttccattttccggcgaaaccgtattcatgtcaatggagaacccagggttgtggatactcggttgccataatagtgacttcagaaaccgagggatgacggcccttctcaaagtaagttcatgtgataagaataccggtgattactacgaagatagctatgaggatattagcgcctacttgcttagcaagaataacgctattgaacctaggagcttttcccagaatagccgacatcctagcactcgccaaaaacagtttaatgcgacaactatccctgagaacgatattgagaaaactgatccctggtttgcacatcgcactcctatgccaaagatccaaaacgtgagcagctctgacctccttatgttgcttagacaatctcccacacctcatggactctcactttccgatctgcaggaggcgaagtatgaaaccttctcagacgacccatccccaggagccatagactcaaacaatagtctctcagaaatgacgcactttagacctcaactccatcacagtggggatatggtatttacccccgagagtggtctgcagcttaggcttaatgaaaaattgggaaccaccgctgcaacggaactcaaaaaactggacttcaaggtttctagcacgtcaaacaatcttatatcaaccataccatccgacaaccttgccgcaggaaccgataacacatcaagcctggggcctccatcaatgccggtgcactatgattcacagttggatactaccctcttcgggaagaaaagttcaccgctgactgaaagcggtggcccactgtctctgagtgaagagaataatgattctaaacttctcgagagcggcctcatgaatagtcaggagagttcttgggggaaaaatgttagcagtactgagagcggacggctcttcaaaggtaagcgggcacatgggcccgctcttctgactaaggataacgctttgttcaaagttagcatatcactcctgaaaactaacaagacctcaaataattctgcaacgaaccggaagacccatattgacggtccaagtttgctcatcgagaactccccgagtgtatggcagaacattcttgagagcgataccgagtttcccccggtactcaagaggcatcagcgggagattacgcgaaccacactccagtccgatcaggaagaaattgattatgacgatactatcagtgtagagatgaaaaaagaagactttgacatctatgatgaggacgagaaccagtctccacgaagctttcagaaaaaaacaaggcactattttatcgccgctgttgaacggctgtgggactacggtatgtcctcttcaccccacgtgctgcggaaccgggcccagtcaggctcagtaccccaattcaagaaggtggtattccaggaatttaccgatggatctttcacgcaacctctttaccgaggtgagctgaacgaacatcttggccttctcggtccttatattagagcagaggtggaagacaatataatggtcacctttcggaaccaagcctccaggccatacagtttctacagttctctgatctcatacgaggaagatcagaggcaaggagcagaaccaaggaagaacttcgtgaaaccaaacgagacaaagacctatttctggaaagttcagcatcatatggcacccactaaagatgagtttgactgcaaagcctgggcttatttctctgatgttgacctggaaaaagatgtgcactcaggcctgattggaccccttctggtctgccacactaacacactgaaccctgctcatgggagacaagtgacagtacaggaatttgctctgtttttcaccatctttgatgagaccaaaagctggtacttcactgaaaatatggaaagaaactgcagggctccctgcaatatccagatggaagatcccacttttaaagagaattatcgcttccatgcaatcaatggctacataatggatacactacctggcttagtaatggctcaggatcaaaggattcgatggtatctgctcagcatgggcagcaatgaaaacatccattctattcatttcagtggacatgtgttcactgtacgaaaaaaagaggagtataaaatggcactgtacaatctctatccaggtgtttttgagacagtggaaatgttaccatccaaagctggaatttggcgggtggaatgccttattggcgagcatctacatgctgggatgagcacactttttctggtgtacagcaataagtgtcagactcccctgggaatggcttctggacacattagagattttcagattacagcttcaggacaatatggacagtgggccccaaagctggccagacttcattattccggatcaatcaatgcctggagcaccaaggagcccttttcttggatcaaggtggatctgttggcaccaatgattattcacggcatcaagacccagggtgcccgtcagaagttctccagcctctacatctctcagtttatcatcatgtatagtcttgatgggaagaagtggcagacttatcgaggaaattccactggaaccttaatggtcttctttggcaatgtggattcatctgggataaaacacaatatttttaaccctccaattattgctcgatacatccgtttgcacccaactcattatagcattcgcagcactcttcgcatggagttgatgggctgtgatttaaatagttgcagcatgccattgggaatggagagtaaagcaatatcagatgcacagattactgcttcatcctactttaccaatatgtttgccacctggtctccttcaaaagctcgacttcacctccaagggaggagtaatgcctggagacctcaggtgaataatccaaaagagtggctgcaagtggacttccagaagacaatgaaagtcacaggagtaactactcagggagtaaaatctctgcttaccagcatgtatgtgaaggagttcctcatctccagcagtcaagatggccatcagtggactctcttttttcagaatggcaaagtaaaggtttttcagggaaatcaagactccttcacacctgtggtgaactctctagacccaccgttactgactcgctaccttcgaattcacccccagagttgggtgcaccagattgccctgaggatggaggttctgggctgcgaggcacaggacctctactga。
本发明的重组凝血因子VIII的编码基因中富含糖基化位点序列,所表达的凝血因子VIII(F8蛋白)具备高效的凝血功能且易于分泌到胞外,易于与辅助因子如凝血酶(FIIa)等相互作用,此外,抗体反应低,能够有效保障治疗效果,降低免疫排斥风险,节约治疗成本。
第三方面,本发明提供一种重组表达载体,所述重组表达载体包括第二方面所述的重组凝血因子VIII的编码基因。
优选地,所述重组表达载体包括含有第二方面所述的重组凝血因子VIII的编码基因的病毒载体或质粒载体。
优选地,所述病毒载体包括慢病毒载体pEGWI。
优选地,所述慢病毒载体pEGWI的5’剪接供体位点GT突变为CA;
优选地,所述慢病毒载体pEGWI的U3区中的增强子缺失;
优选地,所述慢病毒载体pEGWI的U3区中含有静默子。
优选地,所述重组表达载体中包括EF1α启动子。
本发明中,对慢病毒载体pEGWI进行改造,将野生型5’剪接供体位点GT突变为CA,将U3区中的增强子删除,并在U3区中加入静默子(CH4 silencer),不仅能够有效提高pEGWI的转染效率和表达效率,从而降低载体使用成本,还能提高安全性。
第四方面,本发明提供一种重组慢病毒,所述重组慢病毒含有第二方面所述的重组凝血因子VIII的编码基因。
优选地,所述重组慢病毒的制备方法包括:
使用包装质粒对第三方面所述的慢病毒载体进行包装,得到所述重组慢病毒。
优选地,所述包装质粒包括pNHP和pHEF-VSV-G。
优选地,所述重组慢病毒的制备方法包括以下步骤:
(1)将第三方面所述的慢病毒载体与包装辅助质粒pNHP和pHEF-VSV-G共转染哺乳细胞HEK293T中培养24~72h;
(2)进行纯化和浓缩,得到所述重组慢病毒。
第五方面,本发明提供一种重组细胞,所述重组细胞含有第二方面所述的重组凝血因子VIII的编码基因。
优选地,所述重组细胞的基因组中整合有第二方面所述的重组凝血因子VIII的编码基因。
优选地,所述重组细胞含有第三方面所述的重组表达载体。
第六方面,本发明提供一种如第五方面所述的重组细胞的制备方法,所述方法包括:
将第二方面所述的重组凝血因子VIII的编码基因、第三方面所述的重组表达载体或第四方面所述的重组慢病毒导入宿主细胞中,获得所述重组细胞。
优选地,所述导入的方法包括电转导、病毒载体系统、非病毒载体系统或直接基因注射中的任意一种。
优选地,所述宿主细胞包括造血干细胞。
第七方面,本发明提供一种药物组合物,所述药物组合物包括第一方面所述的重组凝血因子VIII、第二方面所述的重组凝血因子VIII的编码基因、第三方面所述的重组表达载体、第四方面所述的重组慢病毒或第五方面所述的重组细胞中的任意一种或至少两种的组合。
优选地,所述药物组合物还包括药学上可接受的载体、赋形剂或稀释剂中的任意一种或至少两种的组合。
第八方面,本发明提供第一方面所述的重组凝血因子VIII、第二方面所述的重组凝血因子VIII的编码基因、第三方面所述的重组表达载体、第四方面所述的重组慢病毒、第五方面所述的重组细胞或第七方面所述的药物组合物在制备治疗血友病药物中的应用。
与现有技术相比,本发明具有以下有益效果:
(1)本发明的重组凝血因子VIII经过基因改造,富含糖基化位点,具备高效的凝血功能且易于分泌到胞外,易于与辅助因子如凝血酶(FIIa)等相互作用,此外,抗体反应低,能够有效保障治疗效果,降低免疫排斥风险,节约治疗成本;
(2)本发明中,对慢病毒载体pEGWI进行改造,不仅能够有效提高pEGWI的转染效率和表达效率,从而降低载体使用成本,而且能提高安全性;
(3)本发明中,利用所述重组凝血因子VIII的编码基因和慢病毒载体构建表达载体,能够成功在A型血友病小鼠体内表达,能一定程度地纠正A型血友病小鼠的出血表型,且抗体反应低,对于保障基因治疗的有效性具有重要的意义,为实现更快的A型血友病症状缓解以及更全面持久的基因治疗奠定了基础。
附图说明
图1为慢病毒载体pEGWI的结构示意图;
图2A为正常F8-BDD基因结构图;
图2B为F8-BDD-N8基因结构图;
图2C为F8-BDD-299基因结构图;
图2D为重组慢病毒载体结构图;
图3为重组慢病毒载体拷贝数;
图4为分析重组慢病毒转染细胞的蛋白质表达量的流程示意图;
图5为重组慢病毒转染细胞的蛋白质表达量结果图;
图6为体外血浆APTT法检测结果图;
图7为体外血浆底物发光法检测结果图;
图8为糖基化抑制剂处理的凝血因子VIII的Westernblot结果图;
图9为体外凝血因子VIII活性图;
图10为治疗A型血友病小鼠的治疗流程示意图;
图11为小鼠体内凝血因子VIII活性图;
图12为小鼠血浆APTT法检测结果图;
图13为小鼠血浆酶联免疫吸附检测结果图。
具体实施方式
为进一步阐述本发明所采取的技术手段及其效果,以下结合实施例和附图对本发明作进一步地说明。可以理解的是,此处所描述的具体实施方式仅仅用于解释本发明,而非对本发明的限定。
实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道商购获得的常规产品。
实施例1
本实施例提供一种慢病毒载体的构建方法,具体包括如下步骤:
(1)慢病毒载体pEGWI的结构示意图如图1所示,将野生型5’剪接供体位点GT突变为CA,将U3中的增强子删除,在U3中加入静默子(CH4 silencer),具体的改造方法可参见“Contributions of Viral Splice Sites and cis-Regulatory Elements toLentivirus Vector Function,Cui et al.Journal of Virology,July 1999,p.6171–6176”;
(2)启动子以及F8-BDD,F8-BDD-N8或F8-BDD-299基因的插入:
通过全基因,与选出可能的糖基化位点序列,进行化学合成正常F8-BDD(序列如SEQ ID NO.7所示)、F8-BDD-N8(序列如SEQ ID NO.5所示)、F8-BDD-299(序列如SEQ IDNO.6所示)基因序列,以及加入人类EF1α启动子序列;正常F8-BDD基因结构图如图2A所示,F8-BDD-N8和F8-BDD-299分别插入了糖基化位点相关序列,基因结构如图2B和2C所示,将其经限制性酶切位点连接入慢病毒载体pEGWI中,通过测序及双酶切(最佳反应条件参照NEB原厂建议),5’端用BamHI克隆位点(ggatccacc)–AUG,3’端用SpeI克隆位点(actagt),对所获产物进行鉴定以获得正确连接的hEF1α启动下携带正常F8-BDD,F8-BDD-N8或F8-BDD-299基因的慢病毒载体,具体的连接位置以及慢病毒载体构成如图2D所示。
SEQ ID NO.7:
atgcagatcgaactgagcacctgcttcttcctgtgtctcctgagattctgctttagtgctaccagacggtattacctgggagccgtcgagctgagttgggattacatgcagtccgacctcggagaactgcctgtggatgcacgctttccaccaagagtgcctaagtcattcccattcaacacctcagtcgtgtataagaagactctgttcgtcgagtttactgatcacctgttcaatatcgctaaacctagaccaccctggatgggactgctgggtcctacaatccaggcagaggtctatgacactgtggtgattacacttaagaacatggcttcccatcctgtcagtcttcatgctgttggtgtatcctactggaaagcttctgagggagctgaatatgatgatcagaccagtcaaagggagaaagaagatgataaagtcttccctggtggaagccatacatatgtctggcaggtcctgaaagagaatggtccaatggcctctgacccactgtgccttacctactcatatctttctcatgtggacctggtaaaagacttgaattcaggcctcattggagccctactagtatgtagagaagggagtctggccaaggaaaagacacagaccttgcacaaatttatactactttttgctgtatttgatgaagggaaaagttggcactcagaaacaaagaactccttgatgcaggatagggatgctgcatctgctcgggcctggcctaaaatgcacacagtcaatggttatgtaaacaggtctctgccaggtctgattggatgccacaggaaatcagtctattggcatgtgattggaatgggcaccactcctgaagtgcactcaatattcctcgaaggtcacacatttcttgtgaggaaccatcgccaggcgtccttggaaatctcgccaataactttccttactgctcaaacactcttgatggaccttggacagtttctactgttttgtcatatctcttcccaccaacatgatggcatggaagcttatgtcaaagtagacagctgtccagaggaaccccaactacgaatgaaaaataatgaagaagcggaagactatgatgatgatcttactgattctgaaatggatgtggtcaggtttgatgatgacaactctccttcctttatccaaattcgctcagttgccaagaagcatcctaaaacttgggtacattacattgctgctgaagaggaggactgggactatgctcccttagtcctcgcccccgatgacagaagttataaaagtcaatatttgaacaatggccctcagcggattggtaggaagtacaaaaaagtccgatttatggcatacacagatgaaacctttaagactcgtgaagctattcagcatgaatcaggaatcttgggacctttactttatggggaagttggagacacactgttgattatatttaagaatcaagcaagcagaccatataacatctaccctcacggaatcactgatgtccgtcctttgtattcaaggagattaccaaaaggtgtaaaacatttgaaggattttccaattctgccaggagaaatattcaaatataaatggacagtgactgtagaagatgggccaactaaatcagatcctcggtgcctgacccgctattactctagtttcgttaatatggagagagatctagcttcaggactcattggccctctcctcatctgctacaaagaatctgtagatcaaagaggaaaccagataatgtcagacaagaggaatgtcatcctgttttctgtatttgatgagaaccgaagctggtacctcacagagaatatacaacgctttctccccaatccagctggagtgcagcttgaggatccagagttccaagcctccaacatcatgcacagcatcaatggctatgtttttgatagtttgcagttgtcagtttgtttgcatgaggtggcatactggtacattctaagcattggagcacagactgacttcctttctgtcttcttctctggatataccttcaaacacaaaatggtctatgaagacacactcaccctattcccattctcaggagaaactgtcttcatgtcgatggaaaacccaggtctatggattctggggtgccacaactcagactttcggaacagaggcatgaccgccttactgaaggtttctagttgtgacaagaacactggtgattattacgaggacagttatgaagatatttcagcatacttgctgagtaaaaacaatgccattgaaccaagaagcttttctcagaatcctcctgtcctcaaacgccatcaacgggagattacacggaccacactccaaagcgatcaggaggagatcgactatgacgataccatatctgtggaaatgaagaaagaggacttcgacatctacgacgaagatgagaaccaaagtccaagatccttccagaagaagactaggcactacttcatcgctgccgtggaacgcctctgggattacggaatgtccagttctccacatgtcctcaggaatagggcacagtctggctctgttccacagtttaagaaagttgtctttcaggagttcacagatggctcattcactcaaccactgtatagaggcgaactgaatgagcacctgggactgctgggtccctacatcagagccgaagtggaggataacattatggtcacctttcggaaccaagcctccaggccatacagtttctacagttctctgatctcatacgaggaagatcagaggcaaggagcagaaccaaggaagaacttcgtgaaaccaaacgagacaaagacctatttctggaaagttcagcatcatatggcacccactaaagatgagtttgactgcaaagcctgggcttatttctctgatgttgacctggaaaaagatgtgcactcaggcctgattggaccccttctggtctgccacactaacacactgaaccctgctcatgggagacaagtgacagtacaggaatttgctctgtttttcaccatctttgatgagaccaaaagctggtacttcactgaaaatatggaaagaaactgcagggctccctgcaatatccagatggaagatcccacttttaaagagaattatcgcttccatgcaatcaatggctacataatggatacactacctggcttagtaatggctcaggatcaaaggattcgatggtatctgctcagcatgggcagcaatgaaaacatccattctattcatttcagtggacatgtgttcactgtacgaaaaaaagaggagtataaaatggcactgtacaatctctatccaggtgtttttgagacagtggaaatgttaccatccaaagctggaatttggcgggtggaatgccttattggcgagcatctacatgctgggatgagcacactttttctggtgtacagcaataagtgtcagactcccctgggaatggcttctggacacattagagattttcagattacagcttcaggacaatatggacagtgggccccaaagctggccagacttcattattccggatcaatcaatgcctggagcaccaaggagcccttttcttggatcaaggtggatctgttggcaccaatgattattcacggcatcaagacccagggtgcccgtcagaagttctccagcctctacatctctcagtttatcatcatgtatagtcttgatgggaagaagtggcagacttatcgaggaaattccactggaaccttaatggtcttctttggcaatgtggattcatctgggataaaacacaatatttttaaccctccaattattgctcgatacatccgtttgcacccaactcattatagcattcgcagcactcttcgcatggagttgatgggctgtgatttaaatagttgcagcatgccattgggaatggagagtaaagcaatatcagatgcacagattactgcttcatcctactttaccaatatgtttgccacctggtctccttcaaaagctcgacttcacctccaagggaggagtaatgcctggagacctcaggtgaataatccaaaagagtggctgcaagtggacttccagaagacaatgaaagtcacaggagtaactactcagggagtaaaatctctgcttaccagcatgtatgtgaaggagttcctcatctccagcagtcaagatggccatcagtggactctcttttttcagaatggcaaagtaaaggtttttcagggaaatcaagactccttcacacctgtggtgaactctctagacccaccgttactgactcgctaccttcgaattcacccccagagttgggtgcaccagattgccctgaggatggaggttctgggctgcgaggcacaggacctctactga。
实施例2
本实施例将实施例1构建得到的慢病毒载体进一步包装、纯化和浓缩,得到所述重组慢病毒,实验方法参考([1]Chang L J,UrlacherV,Iwakuma T,et al.Efficacy andsafety analyses of a recombinant human immunodeficiency virus type 1derivedvector system[J].Gene Therapy,1999,6(5):715-728.[2]Chang L J,ZaissAK.Chang,LJand Zaiss,AK.Lentiviral vectors.Preparation and use.Methods Mol Med69:303-318[J].Methods in molecular medicine,2002,69:303-318.)
具体步骤可以参考上列文献,并简单描述如下:
(1)将实施例1中构建的慢病毒载体与包装辅助质粒pNHP和pHEF-VSV-G共转染哺乳细胞HEK293T中培养48h,收取上清液病毒载体;
(2)将培养收取得到的慢病毒进行纯化和浓缩,得到所述重组慢病毒;
(3)检测慢病毒载体拷贝数(VCN),检测结果如图3所示,运用相同的感染复数,LV-F8-BDD,LV-F8-BDD-N8和LV-F8-BDD-299慢病毒的拷贝数基本相同。
实施例3
本实施例对实施例2制备的重组慢病毒进行体外(invitro)测试。
将实施例2制备的携带正常F8-BDD、F8-BDD-N8或F8-BDD-299基因的3种慢病毒(LV-F8-BDD,LV-F8-BDD-N8和LV-F8-BDD-299)分别转染EA-hy926内皮细胞,慢病毒转染方法包括:
在六孔板(美国康宁)中加入含有10%胎牛血清和1%青霉素-链霉素溶液的DMEM培养基,每孔接种4×104个EA-hy926细胞,于37℃、5%CO2条件下培养18h,以MOI=50进行慢病毒转染,并补充聚凝胺(Polybrene,8μg/mL,Sigma-Aldrich)至培养基终体积为600μL,转染24h,随后每天置换新鲜培养基,待细胞汇合度(confluence)达到90%,将细胞转至T75cm2培养瓶(美国康宁)。
进行蛋白质表达量检测,以明确F8-BDD,F8-BDD-N8和F8-BDD-299基因在细胞中的表达情况,具体过程如图4所示,收集转染后EA-hy926分泌的上清液,进行浓缩,同时收集胞内萃取物,采用Westernblot法检测蛋白质表达量,未经慢病毒转染的细胞作为阴性对照(NC),GAPDH为内参,结果如图5所示,其中L为细胞萃取物检测结果,S为细胞培养上清液检测结果,由图5可知,未经慢病毒转染的细胞中,存在少量凝血因子VIII(F8蛋白)的表达(低活性,43kDa),而经携带正常F8-BDD,F8-BDD-N8或F8-BDD-299基因慢病毒转染后细胞中,可见明显较大量的F8-BDD、F8-BDD-N8或F8-BDD-299表达,且相较于F8-BDD,转染F8-BDD-N8和F8-BDD-299的细胞的上清液中均可获得更完整的F8蛋白(110~200kDa),表明本发明经遗传改造后的F8-BDD基因F8-BDD-N8和F8-BDD-299所表达的凝血因子VIII更易分泌到胞外,从而保证有效发挥凝血效果。
评估凝血功能主要有两种方法,一种为活化部分凝血活酶时间(APTT)测试法,另一种为底物发光测定法。APTT(德国Siemens Healthcare Diagnostics Products GmbH公司)测试方法为在37℃条件下,在50μL受检血浆中加入50μL细胞上清液,再加入100μLAPTT中的Actin试剂(XII因子激活剂和脑磷脂),充分混匀,7℃孵育3分钟,最后加入100μL钙离子(CaCl2),观察血浆凝固所需的时间,即为活化部分凝血活酶时间。
底物发光测定法是一种使用F8 chromogenic assay试剂盒进行活性测定的方法(法国HyphenBioMed公司)。底物发光测试方法为,首先将待测试血浆和空白对照组使用Tris-BSA缓冲液(R4+)稀释40倍后取50μL加入微孔板,然后分别加入X因子(R1),活化的IX因子混合物(R2)和SXa-11底物(R3)各50μL,37℃孵育5分钟,加入50μL 20%乙酸停止反应,在吸光度405nm处读取吸光值。
从-80℃取出上述收集好的病毒转染EA-hy926细胞的上清液,放于冰上融化,分别将各上清液与F8缺陷者血浆混合,以F8缺陷者血浆作为阴性对照(NC),以健康志愿者血浆为阳性对照(PC),采用APTT法和底物发光法进行检测。
图6为APTT法检测的结果,与阴性对照相比,转染F8-BDD细胞的上清液、转染F8-BDD-N8细胞的上清液和转染F8-BDD-299细胞的上清液均有明显的凝血活性效果,血浆凝固时间明显缩短,其中转染F8-BDD-299细胞的上清液效果最佳,凝血时间为94.3秒,与阳性对照(57.5秒)相比,有一定的统计学差异(P<0.05),转染F8-BDD-N8细胞的上清液的凝血时间为113.7秒,与F8-BDD-299和阳性对照相比,也有一定的统计学差异(P均<0.05),转染F8-BDD细胞的上清液的凝血时间为156.7秒,与F8-BDD-N8、F8-BDD-299和阳性对照相比,均有较大的统计学差异(P均<0.001),表明本发明改造的F8-BDD基因F8-BDD-N8和F8-BDD-299所表达的凝血因子VIII具备高效的凝血作用。
图7为底物发光法的检测结果,使用F8 chromogenic assay试剂盒获得活性,再通过ELISA的凝血因子VIII定量,得到单位活性,F8-BDD-299表达的凝血因子VIII的单位活性是F8-BDD表达的凝血因子VIII的100倍,是F8-BDD-N8表达的凝血因子VIII的2.8倍。
综上所述,本发明利用改造的F8-BDD基因F8-BDD-N8和F8-BDD-299分别构建慢病毒载体并在细胞中成功表达,F8-BDD-N8和F8-BDD-299所表达的凝血因子VIII更易分泌到胞外,且具备高效的凝血作用。
实施例4
本实施例检测凝血因子VIII的N-糖基化。
使用糖基化抑制剂—神经氨酸苷酶(N)和肽-N-糖苷酶F(G)分别处理F8-BDD、F8-BDD-N8和F8-BDD-299转导的内皮细胞的上清液,糖基化抑制剂可以诱导去糖基化并降低分子量,Western Blot结果如图8所示,其中“+”表示使用相应酶处理,“-”表示未使用相应酶处理,糖基化抑制剂处理后,如箭头所示为去糖基化后蛋白分子量降低的蛋白条带,F8-BDD-N8和F8-BDD-299表达的凝血因子VIII的分子量明显减少(++泳道对比–泳道),但F8-BDD表达的凝血因子VIII的分子量却没有减少,表明本发明对F8-BDD基因改造后能够有效引入糖基化位点。
凝血酶(FIIa)是凝血因子VIII的重要辅助因子,使用FIIa处理转导内皮细胞的上清液,以研究B结构域修饰是否也影响与促凝辅因子的相互作用,凝血酶的添加增强了F8的激活,并产生更多与凝血因子VIIIa2区相关的蛋白(分子量43kDa)。加入凝血酶后,每隔2分钟进行一次活性检测(如上描述底物发光测定法),结果如图9所示,从第2分钟开始,F8-BDD-299表达的凝血因子VIII的活性大幅度增加,而F8-BDD和F8-BDD-N8的活性增加较平缓。
实施例5
将实施例2制备得到的携带F8-BDD,F8-BDD-N8或F8-BDD-299的3种慢病毒(LV-F8-BDD,LV-F8-BDD-N8和LV-F8-BDD-299)转染小鼠造血干细胞,治疗A型血友病小鼠的治疗流程示意图如图10所示,所使用A型血友病小鼠为敲除F8基因的C57BL/6雌性小鼠(6周龄,购买于北京百奥赛博生物科技有限公司),所有小鼠均被安置在无病原体的环境中,使用x射线照射柜(Faxitron,Tucson,AZ,USA)对小鼠进行照射(9.5Gy/只),从血友病小鼠的胫骨和股骨收集骨髓细胞,并分离其中的造血干细胞,分别以LV-F8-BDD,LV-F8-BDD-N8和LV-F8-BDD-299慢病毒转染,获得携带F8-BDD、F8-BDD-N8或F8-BDD-299基因的干细胞,将转染后的干细胞,以静脉注射的方式回输入A型血友病小鼠体内进行疾病治疗。
分别在同种异体骨髓移植的第15、30、45和60天时,抽取小鼠的血液,从中分离出血浆,分别以未经处理的血友病小鼠(Mock)和野生型小鼠(WT)为对照用底物发光两步法测定血浆凝血因子VIII活性,结果如图11所示,F8-BDD-299表达的凝血因子VIII活性从第15天的5%,增加到第60天的8%,持续增长;而F8-BDD和F8-BDD-N8表达的凝血因子VIII的活性一直维持在3%左右,且均与F8-BDD-299有一定的统计学差异(P<0.05),用APTT法测定血浆凝血功能,结果如图12所示,F8-BDD-299表达的凝血因子VIII的凝血时间最短,最接近于野生型小鼠(P<0.05)。
此外,针对抗体反应,采集上述经过治疗的小鼠眼眶外周血,3000rpm离心15min获得血浆,将血浆1:200用Tris-BSAbuffer稀释,置于PVC微孔板中,加入过氧化物酶标记羊抗鼠IgG(peroxidase-conjugated goat anti-mouse total IgG),随后加发光底物3,3',5,5'-四甲基联苯胺(TMB),进行酶联免疫吸附试验(ELISA),以评估抗凝血因子VIII的抗体反应,以注射抗凝血因子VIII单克隆抗体的A型血友病小鼠作为阳性对照(Ctrl+),结果如图13所示,F8-BDD-N8和F8-BDD-299表达的凝血因子VIII的IgG抗体反应均低于F8-BDD表达的凝血因子VIII,且F8-BDD-299表达的凝血因子VIII的IgG抗体反应最低。
综上所述,本发明对F8-BDD基因进行遗传改造,添加糖基化位点序列,并利用改造后慢病毒载体构建表达载体,所述表达载体具备高转染和表达效率,所表达凝血因子VIII易分泌到胞外,具备高效凝血功能,能一定程度地纠正A型血友病小鼠的出血表型,且抗体反应低,对于保障基因治疗的有效性具有重要的意义,为实现更快的A型血友病症状缓解以及更全面持久的基因治疗奠定了基础。
申请人声明,本发明通过上述实施例来说明本发明的详细方法,但本发明并不局限于上述详细方法,即不意味着本发明必须依赖上述详细方法才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
SEQUENCE LISTING
<110> 北京美康基免生物科技有限公司
<120> 一种重组凝血因子VIII及其应用
<130> 20210425
<160> 7
<170> PatentIn version 3.3
<210> 1
<211> 317
<212> PRT
<213> 人工序列
<400> 1
Glu Asp Pro Glu Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly
1 5 10 15
Tyr Val Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala
20 25 30
Tyr Trp Tyr Ile Leu Ser Ile Gly Ala Gln Thr Asp Phe Leu Ser Val
35 40 45
Phe Phe Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr
50 55 60
Leu Thr Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu
65 70 75 80
Asn Pro Gly Leu Trp Ile Leu Gly Cys His Asn Ser Asp Phe Arg Asn
85 90 95
Arg Gly Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp Lys Asn Thr
100 105 110
Gly Asp Tyr Tyr Glu Asp Ser Tyr Glu Asp Ile Ser Ala Tyr Leu Leu
115 120 125
Ser Lys Asn Asn Ala Ile Glu Pro Arg Ser Phe Ser Gln Asn Ala Thr
130 135 140
Thr Ile Gln Asn Val Ser Ser Asn Asn Ser Leu Ser Asn Asn Leu Ile
145 150 155 160
Ser Thr Asp Asn Thr Ser Ser Glu Glu Asn Asn Asp Ser Lys Asn Val
165 170 175
Ser Ser Asn Asn Ser Ala Pro Pro Val Leu Lys Arg His Gln Arg Glu
180 185 190
Ile Thr Arg Thr Thr Leu Gln Ser Asp Gln Glu Glu Ile Asp Tyr Asp
195 200 205
Asp Thr Ile Ser Val Glu Met Lys Lys Glu Asp Phe Asp Ile Tyr Asp
210 215 220
Glu Asp Glu Asn Gln Ser Pro Arg Ser Phe Gln Lys Lys Thr Arg His
225 230 235 240
Tyr Phe Ile Ala Ala Val Glu Arg Leu Trp Asp Tyr Gly Met Ser Ser
245 250 255
Ser Pro His Val Leu Arg Asn Arg Ala Gln Ser Gly Ser Val Pro Gln
260 265 270
Phe Lys Lys Val Val Phe Gln Glu Phe Thr Asp Gly Ser Phe Thr Gln
275 280 285
Pro Leu Tyr Arg Gly Glu Leu Asn Glu His Leu Gly Leu Leu Gly Pro
290 295 300
Tyr Ile Arg Ala Glu Val Glu Asp Asn Ile Met Val Thr
305 310 315
<210> 2
<211> 571
<212> PRT
<213> 人工序列
<400> 2
Glu Asp Pro Glu Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly
1 5 10 15
Tyr Val Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala
20 25 30
Tyr Trp Tyr Ile Leu Ser Ile Gly Ala Gln Thr Asp Phe Leu Ser Val
35 40 45
Phe Phe Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr
50 55 60
Leu Thr Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu
65 70 75 80
Asn Pro Gly Leu Trp Ile Leu Gly Cys His Asn Ser Asp Phe Arg Asn
85 90 95
Arg Gly Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp Lys Asn Thr
100 105 110
Gly Asp Tyr Tyr Glu Asp Ser Tyr Glu Asp Ile Ser Ala Tyr Leu Leu
115 120 125
Ser Lys Asn Asn Ala Ile Glu Pro Arg Ser Phe Ser Gln Asn Ser Arg
130 135 140
His Pro Ser Thr Arg Gln Lys Gln Phe Asn Ala Thr Thr Ile Pro Glu
145 150 155 160
Asn Asp Ile Glu Lys Thr Asp Pro Trp Phe Ala His Arg Thr Pro Met
165 170 175
Pro Lys Ile Gln Asn Val Ser Ser Ser Asp Leu Leu Met Leu Leu Arg
180 185 190
Gln Ser Pro Thr Pro His Gly Leu Ser Leu Ser Asp Leu Gln Glu Ala
195 200 205
Lys Tyr Glu Thr Phe Ser Asp Asp Pro Ser Pro Gly Ala Ile Asp Ser
210 215 220
Asn Asn Ser Leu Ser Glu Met Thr His Phe Arg Pro Gln Leu His His
225 230 235 240
Ser Gly Asp Met Val Phe Thr Pro Glu Ser Gly Leu Gln Leu Arg Leu
245 250 255
Asn Glu Lys Leu Gly Thr Thr Ala Ala Thr Glu Leu Lys Lys Leu Asp
260 265 270
Phe Lys Val Ser Ser Thr Ser Asn Asn Leu Ile Ser Thr Ile Pro Ser
275 280 285
Asp Asn Leu Ala Ala Gly Thr Asp Asn Thr Ser Ser Leu Gly Pro Pro
290 295 300
Ser Met Pro Val His Tyr Asp Ser Gln Leu Asp Thr Thr Leu Phe Gly
305 310 315 320
Lys Lys Ser Ser Pro Leu Thr Glu Ser Gly Gly Pro Leu Ser Leu Ser
325 330 335
Glu Glu Asn Asn Asp Ser Lys Leu Leu Glu Ser Gly Leu Met Asn Ser
340 345 350
Gln Glu Ser Ser Trp Gly Lys Asn Val Ser Ser Thr Glu Ser Gly Arg
355 360 365
Leu Phe Lys Gly Lys Arg Ala His Gly Pro Ala Leu Leu Thr Lys Asp
370 375 380
Asn Ala Leu Phe Lys Val Ser Ile Ser Leu Leu Lys Thr Asn Lys Thr
385 390 395 400
Ser Asn Asn Ser Ala Thr Asn Arg Lys Thr His Ile Asp Gly Pro Ser
405 410 415
Leu Leu Ile Glu Asn Ser Pro Ser Val Trp Gln Asn Ile Leu Glu Ser
420 425 430
Asp Thr Glu Phe Pro Pro Val Leu Lys Arg His Gln Arg Glu Ile Thr
435 440 445
Arg Thr Thr Leu Gln Ser Asp Gln Glu Glu Ile Asp Tyr Asp Asp Thr
450 455 460
Ile Ser Val Glu Met Lys Lys Glu Asp Phe Asp Ile Tyr Asp Glu Asp
465 470 475 480
Glu Asn Gln Ser Pro Arg Ser Phe Gln Lys Lys Thr Arg His Tyr Phe
485 490 495
Ile Ala Ala Val Glu Arg Leu Trp Asp Tyr Gly Met Ser Ser Ser Pro
500 505 510
His Val Leu Arg Asn Arg Ala Gln Ser Gly Ser Val Pro Gln Phe Lys
515 520 525
Lys Val Val Phe Gln Glu Phe Thr Asp Gly Ser Phe Thr Gln Pro Leu
530 535 540
Tyr Arg Gly Glu Leu Asn Glu His Leu Gly Leu Leu Gly Pro Tyr Ile
545 550 555 560
Arg Ala Glu Val Glu Asp Asn Ile Met Val Thr
565 570
<210> 3
<211> 568
<212> DNA
<213> 人工序列
<400> 3
ctccaataat tcagcgcccc cagtattgaa acgccaccag agggagatca ccagaaccac 60
actgcagtca gaccaagagg aaattgacta tgatgacaca atcagtgtcg aaatgaaaaa 120
agaagacttt gatatttacg atgaggatga aaatcagtca ccaagatcct ttcaaaaaaa 180
aacccgacat tattttatag cagccgtcga acggttgtgg gattatggca tgagctcaag 240
tccacatgta ctgagaaata gggcgcagtc aggaagcgta ccccagttta agaaggttgt 300
attccaagaa ttcacagacg gtagctttac ccagccgctt tatcgaggag agttgaatga 360
gcaccttggt ttgctgggac cgtacatccg cgcagaagtc gaagacaata taatggtcac 420
ctttcggaac caagcctcca ggccatacag tttctacagt tctctgatct catacgagga 480
agatcagagg caaggagcag aaccaaggaa gaacttcgtg aaaccaaacg agacaaagac 540
ctatttctgg aaagttcagc atcatatg 568
<210> 4
<211> 1971
<212> DNA
<213> 人工序列
<400> 4
atgtcagaca agaggaatgt catcctgttt tctgtatttg atgagaaccg aagctggtac 60
ctcacagaga atatacaacg ctttctcccc aatccagctg gagtgcagct tgaggatccg 120
gagtttcagg catccaatat catgcattct ataaacgggt atgtatttga ttctttgcag 180
ttgagtgtgt gtctgcatga ggttgcctac tggtacattc tgtctatagg ggcgcagacg 240
gatttccttt cagtgttctt cagcgggtat acatttaaac ataagatggt atatgaggac 300
accttgacat tgtttccatt ttccggcgaa accgtattca tgtcaatgga gaacccaggg 360
ttgtggatac tcggttgcca taatagtgac ttcagaaacc gagggatgac ggcccttctc 420
aaagtaagtt catgtgataa gaataccggt gattactacg aagatagcta tgaggatatt 480
agcgcctact tgcttagcaa gaataacgct attgaaccta ggagcttttc ccagaatagc 540
cgacatccta gcactcgcca aaaacagttt aatgcgacaa ctatccctga gaacgatatt 600
gagaaaactg atccctggtt tgcacatcgc actcctatgc caaagatcca aaacgtgagc 660
agctctgacc tccttatgtt gcttagacaa tctcccacac ctcatggact ctcactttcc 720
gatctgcagg aggcgaagta tgaaaccttc tcagacgacc catccccagg agccatagac 780
tcaaacaata gtctctcaga aatgacgcac tttagacctc aactccatca cagtggggat 840
atggtattta cccccgagag tggtctgcag cttaggctta atgaaaaatt gggaaccacc 900
gctgcaacgg aactcaaaaa actggacttc aaggtttcta gcacgtcaaa caatcttata 960
tcaaccatac catccgacaa ccttgccgca ggaaccgata acacatcaag cctggggcct 1020
ccatcaatgc cggtgcacta tgattcacag ttggatacta ccctcttcgg gaagaaaagt 1080
tcaccgctga ctgaaagcgg tggcccactg tctctgagtg aagagaataa tgattctaaa 1140
cttctcgaga gcggcctcat gaatagtcag gagagttctt gggggaaaaa tgttagcagt 1200
actgagagcg gacggctctt caaaggtaag cgggcacatg ggcccgctct tctgactaag 1260
gataacgctt tgttcaaagt tagcatatca ctcctgaaaa ctaacaagac ctcaaataat 1320
tctgcaacga accggaagac ccatattgac ggtccaagtt tgctcatcga gaactccccg 1380
agtgtatggc agaacattct tgagagcgat accgagtttc ccccggtact caagaggcat 1440
cagcgggaga ttacgcgaac cacactccag tccgatcagg aagaaattga ttatgacgat 1500
actatcagtg tagagatgaa aaaagaagac tttgacatct atgatgagga cgagaaccag 1560
tctccacgaa gctttcagaa aaaaacaagg cactatttta tcgccgctgt tgaacggctg 1620
tgggactacg gtatgtcctc ttcaccccac gtgctgcgga accgggccca gtcaggctca 1680
gtaccccaat tcaagaaggt ggtattccag gaatttaccg atggatcttt cacgcaacct 1740
ctttaccgag gtgagctgaa cgaacatctt ggccttctcg gtccttatat tagagcagag 1800
gtggaagaca atataatggt cacctttcgg aaccaagcct ccaggccata cagtttctac 1860
agttctctga tctcatacga ggaagatcag aggcaaggag cagaaccaag gaagaacttc 1920
gtgaaaccaa acgagacaaa gacctatttc tggaaagttc agcatcatat g 1971
<210> 5
<211> 4494
<212> DNA
<213> 人工序列
<400> 5
atgcagatcg aactgagcac ctgcttcttc ctgtgtctcc tgagattctg ctttagtgct 60
accagacggt attacctggg agccgtcgag ctgagttggg attacatgca gtccgacctc 120
ggagaactgc ctgtggatgc acgctttcca ccaagagtgc ctaagtcatt cccattcaac 180
acctcagtcg tgtataagaa gactctgttc gtcgagttta ctgatcacct gttcaatatc 240
gctaaaccta gaccaccctg gatgggactg ctgggtccta caatccaggc agaggtctat 300
gacactgtgg tgattacact taagaacatg gcttcccatc ctgtcagtct tcatgctgtt 360
ggtgtatcct actggaaagc ttctgaggga gctgaatatg atgatcagac cagtcaaagg 420
gagaaagaag atgataaagt cttccctggt ggaagccata catatgtctg gcaggtcctg 480
aaagagaatg gtccaatggc ctctgaccca ctgtgcctta cctactcata tctttctcat 540
gtggacctgg taaaagactt gaattcaggc ctcattggag ccctactagt atgtagagaa 600
gggagtctgg ccaaggaaaa gacacagacc ttgcacaaat ttatactact ttttgctgta 660
tttgatgaag ggaaaagttg gcactcagaa acaaagaact ccttgatgca ggatagggat 720
gctgcatctg ctcgggcctg gcctaaaatg cacacagtca atggttatgt aaacaggtct 780
ctgccaggtc tgattggatg ccacaggaaa tcagtctatt ggcatgtgat tggaatgggc 840
accactcctg aagtgcactc aatattcctc gaaggtcaca catttcttgt gaggaaccat 900
cgccaggcgt ccttggaaat ctcgccaata actttcctta ctgctcaaac actcttgatg 960
gaccttggac agtttctact gttttgtcat atctcttccc accaacatga tggcatggaa 1020
gcttatgtca aagtagacag ctgtccagag gaaccccaac tacgaatgaa aaataatgaa 1080
gaagcggaag actatgatga tgatcttact gattctgaaa tggatgtggt caggtttgat 1140
gatgacaact ctccttcctt tatccaaatt cgctcagttg ccaagaagca tcctaaaact 1200
tgggtacatt acattgctgc tgaagaggag gactgggact atgctccctt agtcctcgcc 1260
cccgatgaca gaagttataa aagtcaatat ttgaacaatg gccctcagcg gattggtagg 1320
aagtacaaaa aagtccgatt tatggcatac acagatgaaa cctttaagac tcgtgaagct 1380
attcagcatg aatcaggaat cttgggacct ttactttatg gggaagttgg agacacactg 1440
ttgattatat ttaagaatca agcaagcaga ccatataaca tctaccctca cggaatcact 1500
gatgtccgtc ctttgtattc aaggagatta ccaaaaggtg taaaacattt gaaggatttt 1560
ccaattctgc caggagaaat attcaaatat aaatggacag tgactgtaga agatgggcca 1620
actaaatcag atcctcggtg cctgacccgc tattactcta gtttcgttaa tatggagaga 1680
gatctagctt caggactcat tggccctctc ctcatctgct acaaagaatc tgtagatcaa 1740
agaggaaacc agataatgtc agacaagagg aatgtcatcc tgttttctgt atttgatgag 1800
aaccgaagct ggtacctcac agagaatata caacgctttc tccccaatcc agctggagtg 1860
cagcttgagg atccagaatt tcaggccagt aatataatgc actccatcaa cggatatgtc 1920
tttgactcct tgcaactctc agtgtgtctt cacgaggtgg cctattggta tattctcagc 1980
ataggggccc agactgactt tctgtctgtc ttcttcagcg gatatacttt taagcataag 2040
atggtttatg aggatacatt gacattgttc cctttcagtg gggagaccgt ctttatgtct 2100
atggaaaatc ctgggctctg gatactcggt tgccacaata gtgacttccg aaatcgcgga 2160
atgacagctc tgctgaaagt gtccagttgt gacaaaaaca ccggggacta ttacgaagac 2220
agctatgaag atataagtgc atatttgctc agcaagaaca atgcgattga gccaaggtct 2280
ttcagtcaaa atgctactac catacagaat gtctcttcca ataacagcct ctcaaacaac 2340
ctcatctcaa ctgacaacac ttcttctgag gagaacaatg acagtaagaa tgtgtcctcc 2400
aataattcag cgcccccagt attgaaacgc caccagaggg agatcaccag aaccacactg 2460
cagtcagacc aagaggaaat tgactatgat gacacaatca gtgtcgaaat gaaaaaagaa 2520
gactttgata tttacgatga ggatgaaaat cagtcaccaa gatcctttca aaaaaaaacc 2580
cgacattatt ttatagcagc cgtcgaacgg ttgtgggatt atggcatgag ctcaagtcca 2640
catgtactga gaaatagggc gcagtcagga agcgtacccc agtttaagaa ggttgtattc 2700
caagaattca cagacggtag ctttacccag ccgctttatc gaggagagtt gaatgagcac 2760
cttggtttgc tgggaccgta catccgcgca gaagtcgaag acaatataat ggtcaccttt 2820
cggaaccaag cctccaggcc atacagtttc tacagttctc tgatctcata cgaggaagat 2880
cagaggcaag gagcagaacc aaggaagaac ttcgtgaaac caaacgagac aaagacctat 2940
ttctggaaag ttcagcatca tatggcaccc actaaagatg agtttgactg caaagcctgg 3000
gcttatttct ctgatgttga cctggaaaaa gatgtgcact caggcctgat tggacccctt 3060
ctggtctgcc acactaacac actgaaccct gctcatggga gacaagtgac agtacaggaa 3120
tttgctctgt ttttcaccat ctttgatgag accaaaagct ggtacttcac tgaaaatatg 3180
gaaagaaact gcagggctcc ctgcaatatc cagatggaag atcccacttt taaagagaat 3240
tatcgcttcc atgcaatcaa tggctacata atggatacac tacctggctt agtaatggct 3300
caggatcaaa ggattcgatg gtatctgctc agcatgggca gcaatgaaaa catccattct 3360
attcatttca gtggacatgt gttcactgta cgaaaaaaag aggagtataa aatggcactg 3420
tacaatctct atccaggtgt ttttgagaca gtggaaatgt taccatccaa agctggaatt 3480
tggcgggtgg aatgccttat tggcgagcat ctacatgctg ggatgagcac actttttctg 3540
gtgtacagca ataagtgtca gactcccctg ggaatggctt ctggacacat tagagatttt 3600
cagattacag cttcaggaca atatggacag tgggccccaa agctggccag acttcattat 3660
tccggatcaa tcaatgcctg gagcaccaag gagccctttt cttggatcaa ggtggatctg 3720
ttggcaccaa tgattattca cggcatcaag acccagggtg cccgtcagaa gttctccagc 3780
ctctacatct ctcagtttat catcatgtat agtcttgatg ggaagaagtg gcagacttat 3840
cgaggaaatt ccactggaac cttaatggtc ttctttggca atgtggattc atctgggata 3900
aaacacaata tttttaaccc tccaattatt gctcgataca tccgtttgca cccaactcat 3960
tatagcattc gcagcactct tcgcatggag ttgatgggct gtgatttaaa tagttgcagc 4020
atgccattgg gaatggagag taaagcaata tcagatgcac agattactgc ttcatcctac 4080
tttaccaata tgtttgccac ctggtctcct tcaaaagctc gacttcacct ccaagggagg 4140
agtaatgcct ggagacctca ggtgaataat ccaaaagagt ggctgcaagt ggacttccag 4200
aagacaatga aagtcacagg agtaactact cagggagtaa aatctctgct taccagcatg 4260
tatgtgaagg agttcctcat ctccagcagt caagatggcc atcagtggac tctctttttt 4320
cagaatggca aagtaaaggt ttttcaggga aatcaagact ccttcacacc tgtggtgaac 4380
tctctagacc caccgttact gactcgctac cttcgaattc acccccagag ttgggtgcac 4440
cagattgccc tgaggatgga ggttctgggc tgcgaggcac aggacctcta ctga 4494
<210> 6
<211> 5256
<212> DNA
<213> 人工序列
<400> 6
atgcagatcg aactgagcac ctgcttcttc ctgtgtctcc tgagattctg ctttagtgct 60
accagacggt attacctggg agccgtcgag ctgagttggg attacatgca gtccgacctc 120
ggagaactgc ctgtggatgc acgctttcca ccaagagtgc ctaagtcatt cccattcaac 180
acctcagtcg tgtataagaa gactctgttc gtcgagttta ctgatcacct gttcaatatc 240
gctaaaccta gaccaccctg gatgggactg ctgggtccta caatccaggc agaggtctat 300
gacactgtgg tgattacact taagaacatg gcttcccatc ctgtcagtct tcatgctgtt 360
ggtgtatcct actggaaagc ttctgaggga gctgaatatg atgatcagac cagtcaaagg 420
gagaaagaag atgataaagt cttccctggt ggaagccata catatgtctg gcaggtcctg 480
aaagagaatg gtccaatggc ctctgaccca ctgtgcctta cctactcata tctttctcat 540
gtggacctgg taaaagactt gaattcaggc ctcattggag ccctactagt atgtagagaa 600
gggagtctgg ccaaggaaaa gacacagacc ttgcacaaat ttatactact ttttgctgta 660
tttgatgaag ggaaaagttg gcactcagaa acaaagaact ccttgatgca ggatagggat 720
gctgcatctg ctcgggcctg gcctaaaatg cacacagtca atggttatgt aaacaggtct 780
ctgccaggtc tgattggatg ccacaggaaa tcagtctatt ggcatgtgat tggaatgggc 840
accactcctg aagtgcactc aatattcctc gaaggtcaca catttcttgt gaggaaccat 900
cgccaggcgt ccttggaaat ctcgccaata actttcctta ctgctcaaac actcttgatg 960
gaccttggac agtttctact gttttgtcat atctcttccc accaacatga tggcatggaa 1020
gcttatgtca aagtagacag ctgtccagag gaaccccaac tacgaatgaa aaataatgaa 1080
gaagcggaag actatgatga tgatcttact gattctgaaa tggatgtggt caggtttgat 1140
gatgacaact ctccttcctt tatccaaatt cgctcagttg ccaagaagca tcctaaaact 1200
tgggtacatt acattgctgc tgaagaggag gactgggact atgctccctt agtcctcgcc 1260
cccgatgaca gaagttataa aagtcaatat ttgaacaatg gccctcagcg gattggtagg 1320
aagtacaaaa aagtccgatt tatggcatac acagatgaaa cctttaagac tcgtgaagct 1380
attcagcatg aatcaggaat cttgggacct ttactttatg gggaagttgg agacacactg 1440
ttgattatat ttaagaatca agcaagcaga ccatataaca tctaccctca cggaatcact 1500
gatgtccgtc ctttgtattc aaggagatta ccaaaaggtg taaaacattt gaaggatttt 1560
ccaattctgc caggagaaat attcaaatat aaatggacag tgactgtaga agatgggcca 1620
actaaatcag atcctcggtg cctgacccgc tattactcta gtttcgttaa tatggagaga 1680
gatctagctt caggactcat tggccctctc ctcatctgct acaaagaatc tgtagatcaa 1740
agaggaaacc agataatgtc agacaagagg aatgtcatcc tgttttctgt atttgatgag 1800
aaccgaagct ggtacctcac agagaatata caacgctttc tccccaatcc agctggagtg 1860
cagcttgagg atccggagtt tcaggcatcc aatatcatgc attctataaa cgggtatgta 1920
tttgattctt tgcagttgag tgtgtgtctg catgaggttg cctactggta cattctgtct 1980
ataggggcgc agacggattt cctttcagtg ttcttcagcg ggtatacatt taaacataag 2040
atggtatatg aggacacctt gacattgttt ccattttccg gcgaaaccgt attcatgtca 2100
atggagaacc cagggttgtg gatactcggt tgccataata gtgacttcag aaaccgaggg 2160
atgacggccc ttctcaaagt aagttcatgt gataagaata ccggtgatta ctacgaagat 2220
agctatgagg atattagcgc ctacttgctt agcaagaata acgctattga acctaggagc 2280
ttttcccaga atagccgaca tcctagcact cgccaaaaac agtttaatgc gacaactatc 2340
cctgagaacg atattgagaa aactgatccc tggtttgcac atcgcactcc tatgccaaag 2400
atccaaaacg tgagcagctc tgacctcctt atgttgctta gacaatctcc cacacctcat 2460
ggactctcac tttccgatct gcaggaggcg aagtatgaaa ccttctcaga cgacccatcc 2520
ccaggagcca tagactcaaa caatagtctc tcagaaatga cgcactttag acctcaactc 2580
catcacagtg gggatatggt atttaccccc gagagtggtc tgcagcttag gcttaatgaa 2640
aaattgggaa ccaccgctgc aacggaactc aaaaaactgg acttcaaggt ttctagcacg 2700
tcaaacaatc ttatatcaac cataccatcc gacaaccttg ccgcaggaac cgataacaca 2760
tcaagcctgg ggcctccatc aatgccggtg cactatgatt cacagttgga tactaccctc 2820
ttcgggaaga aaagttcacc gctgactgaa agcggtggcc cactgtctct gagtgaagag 2880
aataatgatt ctaaacttct cgagagcggc ctcatgaata gtcaggagag ttcttggggg 2940
aaaaatgtta gcagtactga gagcggacgg ctcttcaaag gtaagcgggc acatgggccc 3000
gctcttctga ctaaggataa cgctttgttc aaagttagca tatcactcct gaaaactaac 3060
aagacctcaa ataattctgc aacgaaccgg aagacccata ttgacggtcc aagtttgctc 3120
atcgagaact ccccgagtgt atggcagaac attcttgaga gcgataccga gtttcccccg 3180
gtactcaaga ggcatcagcg ggagattacg cgaaccacac tccagtccga tcaggaagaa 3240
attgattatg acgatactat cagtgtagag atgaaaaaag aagactttga catctatgat 3300
gaggacgaga accagtctcc acgaagcttt cagaaaaaaa caaggcacta ttttatcgcc 3360
gctgttgaac ggctgtggga ctacggtatg tcctcttcac cccacgtgct gcggaaccgg 3420
gcccagtcag gctcagtacc ccaattcaag aaggtggtat tccaggaatt taccgatgga 3480
tctttcacgc aacctcttta ccgaggtgag ctgaacgaac atcttggcct tctcggtcct 3540
tatattagag cagaggtgga agacaatata atggtcacct ttcggaacca agcctccagg 3600
ccatacagtt tctacagttc tctgatctca tacgaggaag atcagaggca aggagcagaa 3660
ccaaggaaga acttcgtgaa accaaacgag acaaagacct atttctggaa agttcagcat 3720
catatggcac ccactaaaga tgagtttgac tgcaaagcct gggcttattt ctctgatgtt 3780
gacctggaaa aagatgtgca ctcaggcctg attggacccc ttctggtctg ccacactaac 3840
acactgaacc ctgctcatgg gagacaagtg acagtacagg aatttgctct gtttttcacc 3900
atctttgatg agaccaaaag ctggtacttc actgaaaata tggaaagaaa ctgcagggct 3960
ccctgcaata tccagatgga agatcccact tttaaagaga attatcgctt ccatgcaatc 4020
aatggctaca taatggatac actacctggc ttagtaatgg ctcaggatca aaggattcga 4080
tggtatctgc tcagcatggg cagcaatgaa aacatccatt ctattcattt cagtggacat 4140
gtgttcactg tacgaaaaaa agaggagtat aaaatggcac tgtacaatct ctatccaggt 4200
gtttttgaga cagtggaaat gttaccatcc aaagctggaa tttggcgggt ggaatgcctt 4260
attggcgagc atctacatgc tgggatgagc acactttttc tggtgtacag caataagtgt 4320
cagactcccc tgggaatggc ttctggacac attagagatt ttcagattac agcttcagga 4380
caatatggac agtgggcccc aaagctggcc agacttcatt attccggatc aatcaatgcc 4440
tggagcacca aggagccctt ttcttggatc aaggtggatc tgttggcacc aatgattatt 4500
cacggcatca agacccaggg tgcccgtcag aagttctcca gcctctacat ctctcagttt 4560
atcatcatgt atagtcttga tgggaagaag tggcagactt atcgaggaaa ttccactgga 4620
accttaatgg tcttctttgg caatgtggat tcatctggga taaaacacaa tatttttaac 4680
cctccaatta ttgctcgata catccgtttg cacccaactc attatagcat tcgcagcact 4740
cttcgcatgg agttgatggg ctgtgattta aatagttgca gcatgccatt gggaatggag 4800
agtaaagcaa tatcagatgc acagattact gcttcatcct actttaccaa tatgtttgcc 4860
acctggtctc cttcaaaagc tcgacttcac ctccaaggga ggagtaatgc ctggagacct 4920
caggtgaata atccaaaaga gtggctgcaa gtggacttcc agaagacaat gaaagtcaca 4980
ggagtaacta ctcagggagt aaaatctctg cttaccagca tgtatgtgaa ggagttcctc 5040
atctccagca gtcaagatgg ccatcagtgg actctctttt ttcagaatgg caaagtaaag 5100
gtttttcagg gaaatcaaga ctccttcaca cctgtggtga actctctaga cccaccgtta 5160
ctgactcgct accttcgaat tcacccccag agttgggtgc accagattgc cctgaggatg 5220
gaggttctgg gctgcgaggc acaggacctc tactga 5256
<210> 7
<211> 4374
<212> DNA
<213> 人工序列
<400> 7
atgcagatcg aactgagcac ctgcttcttc ctgtgtctcc tgagattctg ctttagtgct 60
accagacggt attacctggg agccgtcgag ctgagttggg attacatgca gtccgacctc 120
ggagaactgc ctgtggatgc acgctttcca ccaagagtgc ctaagtcatt cccattcaac 180
acctcagtcg tgtataagaa gactctgttc gtcgagttta ctgatcacct gttcaatatc 240
gctaaaccta gaccaccctg gatgggactg ctgggtccta caatccaggc agaggtctat 300
gacactgtgg tgattacact taagaacatg gcttcccatc ctgtcagtct tcatgctgtt 360
ggtgtatcct actggaaagc ttctgaggga gctgaatatg atgatcagac cagtcaaagg 420
gagaaagaag atgataaagt cttccctggt ggaagccata catatgtctg gcaggtcctg 480
aaagagaatg gtccaatggc ctctgaccca ctgtgcctta cctactcata tctttctcat 540
gtggacctgg taaaagactt gaattcaggc ctcattggag ccctactagt atgtagagaa 600
gggagtctgg ccaaggaaaa gacacagacc ttgcacaaat ttatactact ttttgctgta 660
tttgatgaag ggaaaagttg gcactcagaa acaaagaact ccttgatgca ggatagggat 720
gctgcatctg ctcgggcctg gcctaaaatg cacacagtca atggttatgt aaacaggtct 780
ctgccaggtc tgattggatg ccacaggaaa tcagtctatt ggcatgtgat tggaatgggc 840
accactcctg aagtgcactc aatattcctc gaaggtcaca catttcttgt gaggaaccat 900
cgccaggcgt ccttggaaat ctcgccaata actttcctta ctgctcaaac actcttgatg 960
gaccttggac agtttctact gttttgtcat atctcttccc accaacatga tggcatggaa 1020
gcttatgtca aagtagacag ctgtccagag gaaccccaac tacgaatgaa aaataatgaa 1080
gaagcggaag actatgatga tgatcttact gattctgaaa tggatgtggt caggtttgat 1140
gatgacaact ctccttcctt tatccaaatt cgctcagttg ccaagaagca tcctaaaact 1200
tgggtacatt acattgctgc tgaagaggag gactgggact atgctccctt agtcctcgcc 1260
cccgatgaca gaagttataa aagtcaatat ttgaacaatg gccctcagcg gattggtagg 1320
aagtacaaaa aagtccgatt tatggcatac acagatgaaa cctttaagac tcgtgaagct 1380
attcagcatg aatcaggaat cttgggacct ttactttatg gggaagttgg agacacactg 1440
ttgattatat ttaagaatca agcaagcaga ccatataaca tctaccctca cggaatcact 1500
gatgtccgtc ctttgtattc aaggagatta ccaaaaggtg taaaacattt gaaggatttt 1560
ccaattctgc caggagaaat attcaaatat aaatggacag tgactgtaga agatgggcca 1620
actaaatcag atcctcggtg cctgacccgc tattactcta gtttcgttaa tatggagaga 1680
gatctagctt caggactcat tggccctctc ctcatctgct acaaagaatc tgtagatcaa 1740
agaggaaacc agataatgtc agacaagagg aatgtcatcc tgttttctgt atttgatgag 1800
aaccgaagct ggtacctcac agagaatata caacgctttc tccccaatcc agctggagtg 1860
cagcttgagg atccagagtt ccaagcctcc aacatcatgc acagcatcaa tggctatgtt 1920
tttgatagtt tgcagttgtc agtttgtttg catgaggtgg catactggta cattctaagc 1980
attggagcac agactgactt cctttctgtc ttcttctctg gatatacctt caaacacaaa 2040
atggtctatg aagacacact caccctattc ccattctcag gagaaactgt cttcatgtcg 2100
atggaaaacc caggtctatg gattctgggg tgccacaact cagactttcg gaacagaggc 2160
atgaccgcct tactgaaggt ttctagttgt gacaagaaca ctggtgatta ttacgaggac 2220
agttatgaag atatttcagc atacttgctg agtaaaaaca atgccattga accaagaagc 2280
ttttctcaga atcctcctgt cctcaaacgc catcaacggg agattacacg gaccacactc 2340
caaagcgatc aggaggagat cgactatgac gataccatat ctgtggaaat gaagaaagag 2400
gacttcgaca tctacgacga agatgagaac caaagtccaa gatccttcca gaagaagact 2460
aggcactact tcatcgctgc cgtggaacgc ctctgggatt acggaatgtc cagttctcca 2520
catgtcctca ggaatagggc acagtctggc tctgttccac agtttaagaa agttgtcttt 2580
caggagttca cagatggctc attcactcaa ccactgtata gaggcgaact gaatgagcac 2640
ctgggactgc tgggtcccta catcagagcc gaagtggagg ataacattat ggtcaccttt 2700
cggaaccaag cctccaggcc atacagtttc tacagttctc tgatctcata cgaggaagat 2760
cagaggcaag gagcagaacc aaggaagaac ttcgtgaaac caaacgagac aaagacctat 2820
ttctggaaag ttcagcatca tatggcaccc actaaagatg agtttgactg caaagcctgg 2880
gcttatttct ctgatgttga cctggaaaaa gatgtgcact caggcctgat tggacccctt 2940
ctggtctgcc acactaacac actgaaccct gctcatggga gacaagtgac agtacaggaa 3000
tttgctctgt ttttcaccat ctttgatgag accaaaagct ggtacttcac tgaaaatatg 3060
gaaagaaact gcagggctcc ctgcaatatc cagatggaag atcccacttt taaagagaat 3120
tatcgcttcc atgcaatcaa tggctacata atggatacac tacctggctt agtaatggct 3180
caggatcaaa ggattcgatg gtatctgctc agcatgggca gcaatgaaaa catccattct 3240
attcatttca gtggacatgt gttcactgta cgaaaaaaag aggagtataa aatggcactg 3300
tacaatctct atccaggtgt ttttgagaca gtggaaatgt taccatccaa agctggaatt 3360
tggcgggtgg aatgccttat tggcgagcat ctacatgctg ggatgagcac actttttctg 3420
gtgtacagca ataagtgtca gactcccctg ggaatggctt ctggacacat tagagatttt 3480
cagattacag cttcaggaca atatggacag tgggccccaa agctggccag acttcattat 3540
tccggatcaa tcaatgcctg gagcaccaag gagccctttt cttggatcaa ggtggatctg 3600
ttggcaccaa tgattattca cggcatcaag acccagggtg cccgtcagaa gttctccagc 3660
ctctacatct ctcagtttat catcatgtat agtcttgatg ggaagaagtg gcagacttat 3720
cgaggaaatt ccactggaac cttaatggtc ttctttggca atgtggattc atctgggata 3780
aaacacaata tttttaaccc tccaattatt gctcgataca tccgtttgca cccaactcat 3840
tatagcattc gcagcactct tcgcatggag ttgatgggct gtgatttaaa tagttgcagc 3900
atgccattgg gaatggagag taaagcaata tcagatgcac agattactgc ttcatcctac 3960
tttaccaata tgtttgccac ctggtctcct tcaaaagctc gacttcacct ccaagggagg 4020
agtaatgcct ggagacctca ggtgaataat ccaaaagagt ggctgcaagt ggacttccag 4080
aagacaatga aagtcacagg agtaactact cagggagtaa aatctctgct taccagcatg 4140
tatgtgaagg agttcctcat ctccagcagt caagatggcc atcagtggac tctctttttt 4200
cagaatggca aagtaaaggt ttttcaggga aatcaagact ccttcacacc tgtggtgaac 4260
tctctagacc caccgttact gactcgctac cttcgaattc acccccagag ttgggtgcac 4320
cagattgccc tgaggatgga ggttctgggc tgcgaggcac aggacctcta ctga 4374

Claims (16)

1.一种重组凝血因子VIII,其特征在于,所述重组凝血因子VIII的氨基酸序列为由SEQID NO:6所示的核酸序列编码的序列。
2.一种如权利要求1所述的重组凝血因子VIII的编码基因,其特征在于,所述重组凝血因子VIII的编码基因为SEQ ID NO:6所示的核酸序列。
3.一种重组表达载体,其特征在于,所述重组表达载体含有权利要求2所述的重组凝血因子VIII的编码基因。
4.根据权利要求3所述的表达载体,其特征在于,所述重组表达载体包含权利要求2所述的重组凝血因子VIII的编码基因的病毒载体或质粒载体。
5.根据权利要求4所述的表达载体,其特征在于,所述病毒载体包括慢病毒载体pEGWI。
6.根据权利要求5所述的表达载体,其特征在于,所述慢病毒载体pEGWI的U3区中的增强子缺失。
7.一种重组慢病毒,其特征在于,所述重组慢病毒含有权利要求2所述的重组凝血因子VIII的编码基因。
8.一种重组细胞,其特征在于,所述重组细胞含有权利要求2所述的重组凝血因子VIII的编码基因。
9.根据权利要求8所述的重组细胞,其特征在于,所述重组细胞的基因组中整合有权利要求2所述的重组凝血因子VIII的编码基因。
10.根据权利要求8所述的重组细胞,其特征在于,所述重组细胞含有权利要求3所述的重组表达载体。
11.一种如权利要求8所述的重组细胞的制备方法,其特征在于,所述方法包括:
将权利要求2所述的重组凝血因子VIII的编码基因、权利要求3所述的重组表达载体或权利要求7所述的重组慢病毒导入宿主细胞中,获得所述重组细胞。
12.根据权利要求11所述的制备方法,其特征在于,所述导入的方法包括电转导、病毒载体系统、非病毒载体系统或直接基因注射中的任意一种。
13.根据权利要求11所述的制备方法,其特征在于,所述宿主细胞包括造血干细胞。
14.一种药物组合物,其特征在于,所述药物组合物包括权利要求1所述的重组凝血因子VIII、权利要求2所述的重组凝血因子VIII的编码基因、权利要求3所述的重组表达载体、权利要求7所述的重组慢病毒或权利要求8所述的重组细胞中的任意一种或至少两种的组合。
15.根据权利要求14所述的药物组合物,其特征在于,所述药物组合物还包括药学上可接受的载体、赋形剂或稀释剂中的任意一种或至少两种的组合。
16.权利要求1所述的重组凝血因子VIII、权利要求2所述的重组凝血因子VIII的编码基因、权利要求3所述的重组表达载体、权利要求7所述的重组慢病毒、权利要求8所述的重组细胞或权利要求14所述的药物组合物在制备治疗血友病药物中的应用。
CN202110762308.XA 2021-04-26 2021-07-06 一种重组凝血因子viii及其应用 Active CN113248594B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP22794558.1A EP4330276A1 (en) 2021-04-26 2022-04-08 Recombinant coagulation factor viii and use thereof
JP2023560862A JP2024514790A (ja) 2021-04-26 2022-04-08 組換え凝固第viii因子及びその使用
PCT/CN2022/085853 WO2022228087A1 (en) 2021-04-26 2022-04-08 Recombinant coagulation factor viii and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110455812 2021-04-26
CN2021104558125 2021-04-26

Publications (2)

Publication Number Publication Date
CN113248594A CN113248594A (zh) 2021-08-13
CN113248594B true CN113248594B (zh) 2022-08-30

Family

ID=77190753

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110762308.XA Active CN113248594B (zh) 2021-04-26 2021-07-06 一种重组凝血因子viii及其应用

Country Status (4)

Country Link
EP (1) EP4330276A1 (zh)
JP (1) JP2024514790A (zh)
CN (1) CN113248594B (zh)
WO (1) WO2022228087A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113248594B (zh) * 2021-04-26 2022-08-30 北京美康基免生物科技有限公司 一种重组凝血因子viii及其应用
CN114032239A (zh) * 2021-10-28 2022-02-11 北京美康基免生物科技有限公司 一种组织特异启动子及其应用
WO2024007978A1 (zh) * 2022-07-07 2024-01-11 深圳新诺微环生物科技有限公司 一种连接肽、包含连接肽的凝血八因子蛋白或其变体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970481A (zh) * 2007-04-20 2011-02-09 Lfb生物科技公司 用于治疗a型血友病患者的去甘露糖基化的重组因子ⅷ
CN105017410A (zh) * 2014-04-18 2015-11-04 北京诺思兰德生物技术股份有限公司 一种b区部分缺失型重组人凝血因子ⅷ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108795986A (zh) * 2018-05-31 2018-11-13 深圳市免疫基因治疗研究院 一种a型血友病慢病毒载体、慢病毒及其制备方法和应用
CN113248594B (zh) * 2021-04-26 2022-08-30 北京美康基免生物科技有限公司 一种重组凝血因子viii及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970481A (zh) * 2007-04-20 2011-02-09 Lfb生物科技公司 用于治疗a型血友病患者的去甘露糖基化的重组因子ⅷ
CN105017410A (zh) * 2014-04-18 2015-11-04 北京诺思兰德生物技术股份有限公司 一种b区部分缺失型重组人凝血因子ⅷ

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BDD-F8, partial [Cloning vector pCDNA4-BDD-F8];Chen,H. 等;《GenBank: QGN01200.1》;20191126;序列 *
Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse;Jian-Ping Zhang 等;《Genome Biology》;20191216;1-17 *
Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system;L-J Chang 等;《Gene Therapy》;19990514;715-728 *
Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A;Jie Gong 等;《J. Biol. Chem.》;20211110;101397 *

Also Published As

Publication number Publication date
EP4330276A1 (en) 2024-03-06
CN113248594A (zh) 2021-08-13
JP2024514790A (ja) 2024-04-03
WO2022228087A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
CN113248594B (zh) 一种重组凝血因子viii及其应用
US8871439B2 (en) Serum-free stable transfection and production of recombinant human proteins in human cell lines
CN112575034B (zh) 一种治疗a型血友病的产品及应用
EP3250226B1 (en) Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
PT96103B (pt) Processo para a preparacao de proteinas fibrinoliticas e anti-tromboticas activaveis
EP3581650A2 (en) Factor ix polypeptide mutant, its uses and a method for its production
KR20220092583A (ko) 인자 viii 폴리펩타이드
EP3013855B1 (en) Mutant factor viii compositions and methods
US20040005670A1 (en) Compositions and methods for the treatment of hemophilia A
CN114032239A (zh) 一种组织特异启动子及其应用
Percival et al. Investigation of human cyclooxygenase-2 glycosylation heterogeneity and protein expression in insect and mammalian cell expression systems
US20220259287A1 (en) Single chain factor viii molecule
US8017750B2 (en) Haemocoagulase
CN114196677A (zh) 一种高活性的凝血因子Ⅷ或Ⅷa多肽变体Gly710Ala
RU2808564C2 (ru) Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови VIII c делетированным B доменом, и ее применение
US9243237B2 (en) Method for mass production of factor VII/VIIA
WO2014041500A2 (en) Double mutant coagulation factor viii and methods thereof
RU2818229C2 (ru) Выделенная нуклеиновая кислота, которая кодирует слитый белок на основе FVIII-BDD и гетерологичного сигнального пептида, и ее применение
CN114717239A (zh) 一种高活性的凝血因子Ⅷ或Ⅷa多肽变体Gly710Thr
US11795207B2 (en) Modified plasma clotting factor VIII and method of use thereof
Dode et al. Isolation and characterization of the vitamin K dependent domain of human prothrombin
Gao et al. Cloning and expression of canine clotting factor IX cDNA in vitro mediated by retroviral vector
US20210395714A1 (en) Modified factor ix polypeptides
EP4314041A1 (en) Modified plasma clotting factor viii and method of use thereof
WO2023133469A2 (en) Recombinant factor viii variants

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant